Cyproterone Acetate (DB04839): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Cyproterone acetate (CPA) is a potent, synthetic, steroidal agent characterized by a dual mechanism of action, functioning as both a competitive antiandrogen and a powerful progestin.[1] Its primary pharmacodynamic effects are achieved through two synergistic pathways: direct competitive antagonism of the androgen receptor (AR) at peripheral target tissues and central antigonadotropic activity mediated by its progestogenic properties, which suppress the hypothalamic-pituitary-gonadal axis and reduce endogenous testosterone production.[3] This dual action underpins its clinical utility across a wide, dose-dependent spectrum of indications. In low-dose formulations, typically combined with an estrogen, it is used to treat severe acne, hirsutism, and other signs of androgenization in women. In high-dose monotherapy, it serves as a palliative treatment for advanced, inoperable prostate cancer and is used for the reduction of sex drive in men with sexual deviations.[3]

Despite its therapeutic efficacy, the clinical application of cyproterone acetate is constrained by significant safety concerns that have shaped its regulatory status and prescribing guidelines globally. The most critical of these is a dose- and duration-dependent risk of developing intracranial meningiomas, a finding from long-term pharmacovigilance that has prompted major regulatory restrictions, particularly in Europe.[6] Furthermore, CPA is associated with a risk of hepatotoxicity, including rare but potentially fatal cases of liver failure, necessitating rigorous monitoring of hepatic function.[8] The risk of thromboembolic events, especially when used in combination with estrogens, also represents a serious adverse effect.[9]

The global regulatory landscape for cyproterone acetate is notably divergent. It is widely authorized and used in many European countries, Australia, and Canada, albeit with increasingly stringent warnings and restrictions.[5] In stark contrast, it has never been approved for any indication by the U.S. Food and Drug Administration (FDA), reflecting a different assessment of its benefit-risk profile.[11] This complex profile positions cyproterone acetate as a highly effective hormonal agent for specific and often severe conditions, but one whose use demands careful patient selection, strict adherence to the principle of the lowest effective dose for the shortest possible duration, and comprehensive, long-term safety monitoring.

Drug Identification and Physicochemical Properties

Nomenclature and Identifiers

Cyproterone acetate is identified by a variety of generic, brand, and chemical names, as well as unique database and regulatory identifiers. Establishing a clear and comprehensive list of these identifiers is fundamental for accurate cross-referencing in clinical, research, and regulatory contexts. The compound is widely known by its brand name Androcur, particularly when formulated as a high-dose monotherapy, and as a component of combination products such as Diane-35.[3] A consolidated list of its principal identifiers is provided in Table 1.

Table 1: Drug Identification and Nomenclature for Cyproterone Acetate

Identifier Type	Value	Source(s)
Generic Name	Cyproterone acetate	3
DrugBank ID	DB04839	1
CAS Number	427-51-0	1
IUPAC Name	octadeca-7,9-dienyl] acetate	1
InChI	InChI=1S/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1	1
InChIKey	UWFYSQMTEOIJJG-FDTZYFLXSA-N	1
SMILES	CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C	1
Molecular Formula	C24​H29​ClO4​	1
UNII	4KM2BN5JHF	1
ChEBI ID	CHEBI:50743	1
EC Number	207-048-3	1
Synonyms/Codes	CPA, Cyproterone 17-O-acetate, SH 714, NSC-81430, Androcur, Cyprostat	2

Chemical Profile and History

Cyproterone acetate is a synthetic pregnane steroid and is chemically classified as a derivative of 17α-hydroxyprogesterone.[16] Its structure is characterized as a 20-oxo steroid, a 3-oxo-Δ4 steroid, a chlorinated steroid, and a steroid ester, resulting from the formal condensation of an acetic acid carboxy group with the 17-hydroxy group of its parent compound, cyproterone.[1] This esterification is critical to its pharmacological profile, conferring potent progestational activity that the parent molecule lacks.[16]

The compound has a molecular formula of C24​H29​ClO4​ and an average molecular weight of approximately 416.94 g/mol.[3] Historically, cyproterone acetate was developed by the pharmaceutical company Schering AG in West Germany and was first marketed in 1973 under the brand name Androcur.[2] Its development marked a significant advancement in antiandrogen therapy. The long history of its clinical use has been instrumental in the accumulation of extensive post-marketing safety data, which has more recently led to a deeper understanding of its long-term risks and subsequent revisions to its prescribing guidelines.[7]

Physical Properties and Formulation

In its pure form, cyproterone acetate is a white to off-white crystalline solid or powder.[2] Its solubility characteristics are typical of a lipophilic steroid molecule. It is practically insoluble in water but demonstrates good solubility in various organic solvents, including methanol, dimethyl sulfoxide (DMSO), acetone, and methylene chloride, while being only sparingly soluble in ethanol.[2] This solubility profile is a key determinant in its formulation for both oral and parenteral administration and is essential for its handling in laboratory and research settings.

The stability of the compound is robust, with a shelf life of at least four years when stored under appropriate conditions.[14] Standard storage recommendations include keeping it in a sealed, dry container, protected from heat and light, at refrigerated (2-8°C) or frozen (<0°C) temperatures to ensure its chemical integrity.[14]

Cyproterone acetate is available in several pharmaceutical formulations to suit its diverse clinical applications. The most common forms are oral tablets, which are available in a range of strengths, including 10 mg, 50 mg, and 100 mg.[6] Additionally, a depot formulation is available as a solution for intramuscular injection, typically at a concentration of 300 mg/3 ml, providing a long-acting therapeutic option.[6]

Comprehensive Pharmacology

Pharmacodynamics (Mechanism of Action)

The high therapeutic efficacy of cyproterone acetate stems from a sophisticated and potent dual-action mechanism that distinguishes it from many other antiandrogenic agents. It combines direct, peripheral blockade of androgen action with a powerful, central suppression of androgen synthesis. This synergistic approach provides a more comprehensive and profound antiandrogenic effect than would be achievable by either mechanism alone. The key to this dual action lies in the chemical structure of cyproterone acetate itself. Its parent compound, cyproterone, is a "pure" androgen receptor antagonist with virtually no progestational activity.[16] The addition of the acetate group at the C17 position transforms the molecule, conferring potent progestational properties.[16] It is this progestational activity that mediates the central suppression of testosterone production. In contrast, a pure receptor antagonist would only block the action of existing circulating androgens, which could lead to a compensatory increase in luteinizing hormone (LH) and testosterone levels. By simultaneously blocking the receptor and shutting down testosterone production at its source in the testes, cyproterone acetate achieves a state of profound androgen deprivation, which is the basis of its clinical effectiveness.[1]

The specific mechanisms are detailed as follows:

1. Competitive Androgen Receptor (AR) Antagonism: At the cellular level, CPA acts as a competitive antagonist at the androgen receptor. It binds with high affinity to ARs in target tissues—such as the prostate gland, sebaceous glands of the skin, and hair follicles—thereby preventing the binding and subsequent action of endogenous androgens like testosterone and its more potent metabolite, dihydrotestosterone (DHT).[3] This direct blockade inhibits androgen-mediated gene transcription and cellular processes. In vitro studies have quantified this high affinity, with reported half-maximal inhibitory concentration ( IC50​) values of 7.1 nM and 26 nM for inhibiting AR activation.[2] It is noteworthy that at very high, supra-physiological concentrations, CPA can exhibit weak partial agonist activity at the AR (half-maximal effective concentration, EC50​, of 4.0 μM), a characteristic of some steroidal antagonists, though the clinical relevance of this effect is likely minimal under therapeutic dosing.[23]
2. Progestogenic and Antigonadotropic Activity: CPA is a potent agonist of the progesterone receptor (PR).[1] This strong progestational activity is the cornerstone of its second mechanism of action. By activating PRs in the hypothalamus and pituitary gland, CPA exerts a powerful negative feedback effect on the hypothalamic-pituitary-gonadal (HPG) axis.[2] This feedback loop leads to a marked reduction in the pulsatile secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus and, consequently, a suppression of luteinizing hormone (LH) secretion from the pituitary gland.[1] Since LH is the primary signal for testosterone production by the Leydig cells in the testes, the reduction in LH levels results in significantly diminished testicular testosterone synthesis and lower circulating serum testosterone concentrations.[4]
3. Weak Glucocorticoid Activity: At higher therapeutic doses, CPA also demonstrates weak agonist activity at the glucocorticoid receptor.[16] While this effect is much less potent than that of dedicated corticosteroids like prednisone, it is clinically significant.[16] This activity can lead to a mild suppression of the hypothalamic-pituitary-adrenal (HPA) axis and adrenocortical function. This requires clinical consideration, particularly regarding the potential for adrenal insufficiency upon abrupt discontinuation of long-term, high-dose therapy.[24]

Pharmacokinetics (ADME)

The pharmacokinetic profile of cyproterone acetate, detailing its absorption, distribution, metabolism, and excretion (ADME), is crucial for understanding its dosing regimens, duration of action, and potential for drug interactions. Its characteristics are defined by high oral bioavailability, extensive protein binding, and a long elimination half-life.

• Absorption: Following oral administration, cyproterone acetate is completely and rapidly absorbed from the gastrointestinal tract.[3] Its oral bioavailability is high, though variable, reported to be in the range of 68% to 100%.[10] Peak plasma concentrations ( Tmax​) are typically reached within 3 to 4 hours after a single oral dose.[25]
• Distribution: Once in the systemic circulation, CPA is extensively bound to plasma proteins, primarily albumin.[10] The protein-bound fraction is very high, estimated at 93% to 96%, leaving only a small fraction (4-7%) of the drug unbound and pharmacologically active.[2] The volume of distribution has not been well-characterized but is expected to be large given its lipophilic nature.
• Metabolism: CPA undergoes extensive hepatic metabolism.[3] The primary metabolic pathway is hydroxylation, mediated predominantly by the cytochrome P450 3A4 (CYP3A4) enzyme system.[3] This reliance on CYP3A4 is a critical factor in its susceptibility to drug-drug interactions. The major metabolite formed is 15β-hydroxycyproterone acetate, which is pharmacologically active. This metabolite retains significant antiandrogenic activity but possesses reduced progestational activity compared to the parent compound.[3] Other minor metabolites that have been identified include the deacetylated parent compound, cyproterone, and acetic acid.[10]
• Excretion: The elimination of cyproterone acetate is biphasic and occurs primarily through the hepatobiliary route. Approximately 60-70% of an administered dose is excreted in the bile and subsequently eliminated in the feces, largely in the form of glucuronidated metabolites.[3] The remaining 30-33% is excreted via the kidneys into the urine, predominantly as unconjugated metabolites.[3]
• Half-Life: The drug has a relatively long terminal elimination half-life, which contributes to its sustained therapeutic effect and allows for convenient dosing schedules. Following oral administration, the plasma half-life is reported to be between 38 hours and 4.3 days (approximately 1.6 to 4.3 days).[3] After intramuscular depot injection, the half-life is extended further, to approximately 96 hours (4 days).[3]

The key pharmacokinetic parameters of cyproterone acetate are summarized in Table 2.

Table 2: Key Pharmacokinetic Parameters of Cyproterone Acetate

Parameter	Value	Source(s)
Oral Bioavailability	68–100%	10
Time to Peak (Tmax​)	3–4 hours	25
Protein Binding	93–96% (to albumin)	2
Metabolism Pathway	Hepatic (primarily CYP3A4)	3
Major Active Metabolite	15β-hydroxycyproterone acetate	3
Elimination Half-life	Oral: 1.6–4.3 days (38–103 hours) IM: ~4 days (96 hours)	3
Excretion	Feces: ~60–70% Urine: ~30–33%	3

Clinical Applications and Therapeutic Efficacy

The clinical application of cyproterone acetate is a compelling illustration of how the perception of a drug's benefit-risk profile can evolve over time with the accumulation of long-term safety data. Initially introduced and widely used for a broad range of androgen-dependent conditions, its therapeutic role has been significantly refined and, in some cases, restricted by regulatory agencies. This shift has been driven primarily by a growing understanding of serious long-term risks, most notably the association with intracranial meningiomas.

Historically, CPA was often considered a first-line therapy for conditions like severe acne and hirsutism in women.[3] However, the landscape changed dramatically following a 2020 safety review by the European Medicines Agency (EMA). This review, prompted by evidence linking cumulative CPA exposure to an increased risk of meningioma, led to new recommendations that fundamentally altered its place in therapy.[6] For non-life-threatening but distressing dermatological conditions, high-dose CPA (≥10 mg/day) was relegated to a second- or third-line option, to be used only after other treatments have failed.[6] This regulatory action underscores a critical principle in pharmacotherapy: the acceptability of risk is contingent on the severity of the condition being treated. For a life-threatening disease like inoperable prostate cancer, the significant risks associated with CPA may be deemed acceptable. For cosmetic or non-fatal conditions, the same level of risk is not. This dynamic re-evaluation has resulted in a stratified and more cautious approach to its use, reflecting a mature and evidence-based understanding of its long-term consequences.

Approved Indications (Region-Specific Analysis)

The regulatory approval and specific indications for cyproterone acetate vary significantly between different international jurisdictions, highlighting divergent assessments of its efficacy and safety.

• European Union (EMA):
• Prostate Cancer: The indication for the palliative, antiandrogen treatment of inoperable prostate cancer remains unchanged. This includes its use to prevent the initial "tumor flare" phenomenon associated with the initiation of luteinizing hormone-releasing hormone (LHRH) agonist therapy.[6]
• Androgen-Dependent Conditions in Women: The use of higher-dose CPA formulations (10 mg or more) for conditions such as hirsutism, androgenic alopecia, acne, and seborrhea is now restricted. It is indicated only after other treatment options, including lower-dose combination products (e.g., CPA 2 mg/ethinylestradiol 35 micrograms), have proven ineffective. Once a clinical improvement is observed, the dose should be gradually tapered to the lowest effective maintenance dose.[6]
• Reduction of Sex Drive in Men: This indication is also restricted and should only be considered when other treatment options are deemed unsuitable or have failed.[6]
• Australia (Therapeutic Goods Administration - TGA):
• Men: CPA is approved for several indications, including the palliative treatment of inoperable prostatic carcinoma (both for long-term therapy and for suppressing flare with LHRH analogues), the reduction of drive in sexual deviations, and the management of hot flushes in patients undergoing androgen deprivation therapy.[5]
• Women: It is approved for the treatment of moderately severe to severe signs of androgenization, which includes hirsutism, androgenic alopecia, and severe forms of acne and/or seborrhea.[5] The approved indications in Australia appear broader and less explicitly restricted than the current EMA guidelines.
• Canada (Health Canada):
• The primary approved indication in Canada is for the palliative treatment of advanced prostatic carcinoma.[24] It is also indicated, but as a second-line agent, for the treatment of severe acne and hirsutism that has not responded to other available treatments.[11]
• United States (Food and Drug Administration - FDA):
• Cyproterone acetate is not approved for any medical use in the United States.[11] In 1984, it was granted an orphan drug designation for the treatment of severe hirsutism, but this designation was subsequently withdrawn or revoked.[12] This lack of approval signifies a long-standing negative assessment of its benefit-risk profile by the FDA, making it a notable outlier compared to other major regulatory bodies.

Off-Label and Investigational Uses

Beyond its formally approved indications, cyproterone acetate is used off-label in several clinical contexts, most prominently in transgender healthcare.

• Transgender Hormone Therapy: CPA is widely used, particularly in Europe and Canada, as the antiandrogen component of feminizing hormone therapy for transgender women.[10] It is valued for its high efficacy in suppressing endogenous testosterone production. Importantly, recent research has provided practice-changing evidence regarding its optimal dosing in this population. A large longitudinal study demonstrated that a low daily dose of 10 mg of CPA is equally as effective as higher doses (25 mg, 50 mg, or 100 mg) in suppressing serum testosterone to the desired female range (below 2 nmol/L).[33] The study also found that the lower dose was associated with fewer side effects, such as hyperprolactinemia.[33] This finding strongly supports a shift towards using much lower doses in this clinical setting to minimize long-term risks.
• Polycystic Ovary Syndrome (PCOS): CPA is used to manage the hyperandrogenic symptoms of PCOS, such as hirsutism and acne. In this context, it is almost always prescribed in combination with an estrogen to provide cycle control and prevent endometrial hyperplasia.[10]
• Contraception: While low-dose combinations of CPA (2 mg) and ethinylestradiol (35 micrograms), such as Diane-35, are approved as oral contraceptives that also treat androgen-sensitive acne, higher-dose CPA monotherapy also exerts a potent contraceptive effect by inhibiting ovulation.[10] However, it is not formally licensed or recommended solely for the purpose of contraception.[30]

Clinical Trial Evidence

The efficacy of cyproterone acetate in its key indications is supported by data from numerous clinical trials conducted over several decades.

• Acne Vulgaris: The efficacy of CPA in combination with ethinylestradiol for treating acne is well-established. Clinical studies have shown that this combination leads to an overall improvement in 75% to 90% of women, with some cohorts approaching 100% improvement.[10] A completed Phase 4 clinical trial (NCT00752635) provided comparative efficacy and safety data against another combination oral contraceptive (norgestimate-ethinyl estradiol), further substantiating its role in the management of acne vulgaris.[36]
• Prostate Cancer: The role of CPA in advanced prostate cancer has been validated in multiple Phase 3 clinical trials. For instance, trial NCT00849082 evaluated its use in conjunction with radiation therapy, while trial NCT00003653 included CPA as a therapeutic option in a study of various hormonal therapies for patients with biochemically recurrent prostate cancer following radiation.[37] Its effectiveness in preventing the initial disease flare caused by LHRH agonists is also well-documented in clinical studies, where it has been shown to mitigate the temporary surge in testosterone and associated symptoms.[4]

Safety Profile, Tolerability, and Risk Management

The therapeutic use of cyproterone acetate is fundamentally governed by its extensive and significant safety profile. The adverse effects are largely predictable consequences of its potent hormonal actions—namely, profound androgen deprivation and strong progestogenic activity. While many side effects are manageable, several are severe and potentially life-threatening, necessitating careful patient selection, informed consent, and diligent monitoring.

Adverse Drug Reactions

The adverse reaction profile of CPA is dose-dependent and differs between sexes due to its hormonal mechanism.

• Effects Due to Androgen Deprivation (Hypogonadism):
• In Men: The most common side effects are direct results of testosterone suppression and AR blockade. These include a significant decrease in libido, erectile dysfunction, and reduced ejaculate volume, with reversible infertility due to inhibition of spermatogenesis and azoospermia.[10] Feminizing effects such as gynecomastia (breast tissue development), which may be accompanied by tenderness, are also common.[10] Systemic effects include fatigue, depressive mood changes, hot flashes, and sweating.[10] Long-term androgen deprivation therapy with high-dose CPA poses a risk for decreased bone mineral density (osteoporosis) and anemia.[9]
• In Women: The antigonadotropic effects lead to inhibition of ovulation and subsequent reversible infertility.[10] Menstrual irregularities, such as intermenstrual spotting or amenorrhea, are common, as is breast pain or tenderness.[10]
• General and Progestogenic Effects:
• Metabolic and Weight: Weight gain is a frequently reported side effect, particularly at higher doses.[10] CPA can also impair carbohydrate metabolism, potentially increasing insulin requirements in patients with diabetes mellitus.[24] Alterations in plasma lipid profiles have also been noted.[25]
• Central Nervous System: Fatigue and depressed mood are common, especially during the initial weeks of therapy.[10] Restlessness and headache are also reported.[10]
• Gastrointestinal: Nausea and other gastrointestinal complaints can occur.[10]
• Endocrine: Due to its weak glucocorticoid activity, CPA can cause suppression of the adrenal axis. Abrupt discontinuation from high doses can precipitate adrenal insufficiency.[24] Dose-dependent hyperprolactinemia (elevated prolactin levels) is another potential side effect, linked to its progestogenic activity.[10]

Boxed Warnings and Significant Risks

Beyond the common side effects, CPA is associated with several severe risks that have led to major regulatory warnings and changes in clinical practice.

• Meningioma: The most significant safety concern to emerge in recent years is the established association between cyproterone acetate use and an increased risk of developing intracranial meningiomas (typically benign tumors of the membranes surrounding the brain and spinal cord). This risk was not identified in early clinical trials but became apparent through decades of post-marketing surveillance and pharmacoepidemiological studies. The evidence demonstrates a clear relationship with both the cumulative dose and the duration of treatment.[6] The risk becomes particularly significant with long-term use (several years) at doses of 25 mg per day or higher.[6] This discovery was the primary driver for the EMA's 2020 decision to restrict the use of high-dose CPA and to contraindicate it in any patient with a current or past history of meningioma.[6] Clinical practice guidelines now mandate that patients be monitored for neurological symptoms such as changes in vision, hearing loss, persistent headaches, or seizures. If a meningioma is diagnosed, treatment with any cyproterone-containing product must be permanently discontinued.[6] This latent, severe risk has fundamentally altered the benefit-risk assessment for CPA, especially in non-life-threatening conditions.
• Hepatotoxicity: CPA is associated with direct hepatotoxicity, which can range from asymptomatic elevations in liver enzymes (a very common finding) to severe liver injury, including jaundice, hepatitis, and, in rare instances, fulminant hepatic failure, which can be fatal.[8] Benign and malignant primary liver tumors have also been reported in patients after long-term use.[9] This risk is dose-related and typically develops several months after initiating therapy. Consequently, liver function tests (including transaminases, bilirubin, and alkaline phosphatase) are mandatory at baseline before starting treatment and must be monitored regularly throughout therapy, especially if symptoms suggestive of liver injury (e.g., jaundice, dark urine, abdominal pain, persistent fatigue) occur.[9]
• Thromboembolism: An increased risk of thromboembolic events, such as deep vein thrombosis (DVT) and pulmonary embolism (PE), is a recognized risk associated with CPA.[9] The risk is thought to be higher when CPA is used in combination with estrogens, as is common in oral contraceptives and in therapy for women with androgenization.[11] Therefore, it should be used with extreme caution in patients with a personal or family history of thromboembolic disease.[24]

Contraindications

Based on its pharmacological actions and significant risks, cyproterone acetate is contraindicated in several patient populations. The absolute contraindications include:

• Pregnancy and breastfeeding.[40]
• Presence or history of intracranial meningioma.[6]
• Active liver disease, including severe hepatic dysfunction, Dubin-Johnson syndrome, and Rotor syndrome.[24]
• Previous or existing liver tumors (unless they are metastases from prostatic carcinoma).[24]
• History of jaundice or persistent itching during a previous pregnancy.[41]
• History of or existing thromboembolic processes (e.g., DVT, PE, stroke, myocardial infarction).[24]
• Severe chronic depression.[24]
• Wasting diseases (cachexia), with the exception of inoperable prostatic carcinoma.[24]
• Severe diabetes with vascular changes and sickle-cell anemia.[40]
• Known hypersensitivity to cyproterone acetate or any of the excipients in the formulation.[40]

Drug-Drug Interactions

As a primary substrate of the CYP3A4 enzyme, cyproterone acetate is highly susceptible to clinically significant drug-drug interactions (DDIs). Co-administration with drugs that inhibit or induce this enzyme can alter CPA plasma concentrations, potentially leading to increased toxicity or therapeutic failure, respectively. A summary of key interactions is provided in Table 3.

Table 3: Clinically Significant Drug-Drug Interactions with Cyproterone Acetate

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir, amprenavir, atazanavir, amiodarone)	Inhibition of CYP3A4-mediated metabolism of CPA	Increased plasma concentrations of CPA, leading to an elevated risk of dose-dependent adverse effects (e.g., hepatotoxicity, depression).	Avoid concomitant use if possible. If necessary, consider a lower dose of CPA and monitor closely for signs of toxicity.	3
Strong CYP3A4 Inducers (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, aminoglutethimide, St. John's Wort)	Induction of CYP3A4-mediated metabolism of CPA	Decreased plasma concentrations of CPA, potentially leading to loss of therapeutic efficacy.	Avoid concomitant use. If unavoidable, an increased dose of CPA may be required. Monitor for therapeutic response.	3
Antidiabetic Agents (e.g., metformin, sulfonylureas like acetohexamide, insulin)	Pharmacodynamic antagonism; CPA may impair carbohydrate metabolism and increase blood glucose levels.	Decreased therapeutic efficacy of antidiabetic agents, leading to hyperglycemia and potential loss of glycemic control.	Monitor blood glucose levels closely, especially when initiating or adjusting the CPA dose. The dose of the antidiabetic agent may need to be increased.	3
Anticoagulants/Antiplatelets (e.g., warfarin, apixaban, abciximab)	Additive pharmacodynamic effect; potential to increase the risk of bleeding.	Increased risk of bleeding or adverse hemorrhagic events.	Use with caution. Monitor coagulation parameters (e.g., INR for warfarin) and for signs of bleeding.	3
Statins (e.g., atorvastatin, simvastatin)	CPA may inhibit the metabolism of some statins that are also CYP3A4 substrates.	Increased plasma concentrations of the statin, elevating the risk of myopathy and rhabdomyolysis.	Use with caution. Consider using a statin that is not primarily metabolized by CYP3A4 (e.g., pravastatin, rosuvastatin). Monitor for muscle pain or weakness.	3

Dosage, Administration, and Regulatory Status

Prescribing Information and Administration

The dosage of cyproterone acetate is highly individualized and varies significantly based on the indication, the patient's sex, and the desired therapeutic outcome. To minimize gastrointestinal side effects, it is recommended that the tablets be taken with liquid immediately after meals.[21] Adherence to a consistent daily schedule is advised to maintain stable plasma concentrations.[41]

• For Inoperable Prostate Cancer in Men:
• The typical daily dose ranges from 100 mg to 300 mg, administered in two to three divided doses.[25]
• For preventing tumor flare with LHRH agonist initiation, a dose of 200-300 mg/day is often used.[19]
• Following surgical orchiectomy, a lower dose of 100-200 mg/day may be sufficient as the primary source of testosterone has been removed.[25]
• For Reduction of Sex Drive in Men:
• Treatment is typically initiated at 100 mg per day (50 mg twice daily).[19]
• The dose may be temporarily increased to 200-300 mg per day if necessary to achieve adequate control, after which it should be gradually tapered to the lowest effective maintenance dose, which may be as low as 25-50 mg per day.[19]
• For Signs of Androgenization in Women:
• Treatment in premenopausal women requires a cyclical regimen to ensure contraceptive protection and maintain regular withdrawal bleeding. It must be co-administered with a combined oral contraceptive.[19]
• A common regimen involves taking CPA at a dose of 25 mg to 100 mg daily for the first 10 days of the menstrual cycle (starting on day 1 of bleeding), in conjunction with a daily oral contraceptive. After the 10 days of CPA, the oral contraceptive is continued alone for another 11 days, followed by a 7-day tablet-free interval to allow for withdrawal bleeding.[10]
• In postmenopausal or hysterectomized women, CPA can be administered as monotherapy. A typical regimen is 25-50 mg once daily for 21 days, followed by a 7-day tablet-free interval.[19]

Global Regulatory Landscape (Comparative Analysis)

The international regulatory status of cyproterone acetate provides a clear example of how different national agencies can arrive at different conclusions regarding a drug's benefit-risk balance.

• European Union (EMA): CPA is approved and widely used, but its regulation has become increasingly stringent. The 2020 EMA safety review led to significant restrictions on its use for non-oncological indications due to the meningioma risk. High-dose formulations (≥10 mg) are now considered second-line therapies for dermatological conditions, and a contraindication for patients with a history of meningioma has been implemented across the EU.[6]
• Australia (TGA): CPA is approved as a Schedule 4 (Prescription Only Medicine) for a range of indications in both men and women, including prostate cancer, sexual deviations, and severe signs of androgenization.[5] While the product information contains warnings about its risks, the formal indications do not appear to carry the same level of explicit restriction as those mandated by the EMA.
• United States (FDA): In a stark contrast, CPA has never been approved for any indication in the US.[11] This long-standing non-approval, including the eventual revocation of an early orphan drug designation, suggests that from the FDA's perspective, the drug's safety risks have consistently been judged to outweigh its potential benefits for the US population. This divergence remains a key feature of its global regulatory history.
• Other Regions: The drug is approved in Canada for the palliative treatment of prostate cancer and as a second-line agent for severe acne and hirsutism.[11] It is also available in many other parts of the world, including Asia, as indicated by advisories from regulatory bodies like the Philippines FDA concerning unregistered versions of the product.[45]

Concluding Analysis and Expert Recommendations

Synthesis of the Benefit-Risk Profile

Cyproterone acetate is a hormonal agent of considerable potency and undeniable efficacy in the management of specific, often severe, androgen-dependent conditions. Its dual-action mechanism, combining peripheral androgen receptor blockade with central suppression of testosterone synthesis, makes it one of the most powerful antiandrogens available. However, this high efficacy is inextricably linked to a formidable and complex safety profile. The benefit-risk assessment for CPA is not static; it is highly dependent on the clinical indication, the dose and duration of therapy, and the individual patient's baseline health status.

The benefit is most clearly established in the palliative setting for patients with advanced, inoperable prostate cancer. In this context, where the prognosis is poor and the goal is to alleviate symptoms and slow disease progression, the serious long-term risks associated with CPA, such as meningioma, may be considered acceptable. Conversely, the benefit-risk calculation becomes far more challenging for non-life-threatening conditions. For women with severe acne or hirsutism, the potential for a cure or significant symptomatic relief must be carefully weighed against the long-term, cumulative risk of developing a brain tumor, as well as the risks of hepatotoxicity and thromboembolism. The recent regulatory actions in Europe, relegating CPA to a second- or third-line agent for these conditions, reflect a consensus that the risks are too substantial for first-line use when safer alternatives exist.

Expert Recommendations for Clinical Practice

Based on the comprehensive analysis of its pharmacology, efficacy, and safety, the following recommendations are provided to guide the safe and effective use of cyproterone acetate in clinical practice:

1. Strict Patient Selection and Adherence to Indications: The use of CPA should be strictly limited to its approved indications. For androgen-dependent dermatological conditions in women, it should be reserved for severe cases where other, safer therapeutic options (e.g., topical therapies, antibiotics, spironolactone, or lower-risk oral contraceptives) have failed or are contraindicated.
2. Thorough Informed Consent: Prior to initiating therapy, a comprehensive discussion with the patient is ethically and medically imperative. This discussion must explicitly cover the potential for both short-term side effects and serious long-term risks, with particular emphasis on the dose- and duration-dependent risk of meningioma, the potential for severe liver injury, and the risk of thromboembolic events.
3. Principle of Lowest Effective Dose: The clinical strategy must be guided by the principle of using the lowest effective dose for the shortest possible duration. The recent evidence demonstrating the efficacy of a 10 mg daily dose for testosterone suppression in transgender women is highly significant and should inform prescribing practices to minimize cumulative exposure and long-term risk.[33] Doses should be periodically re-evaluated and tapered if clinical improvement is maintained.
4. Mandatory and Rigorous Monitoring:

• Hepatic Function: Liver function tests (LFTs) must be performed at baseline and monitored regularly throughout the course of treatment. Patients should be educated on the signs and symptoms of hepatotoxicity and instructed to report them immediately.
• Neurological Assessment: Both clinicians and patients must remain vigilant for any new or worsening neurological symptoms (e.g., changes in vision or hearing, persistent headaches, seizures, memory loss, focal weakness) that could be indicative of a meningioma. Any such symptoms warrant immediate investigation.
• Metabolic Parameters: In patients with diabetes mellitus, blood glucose levels must be monitored closely, as CPA can affect glycemic control. Periodic assessment of lipid profiles should also be considered.

5. Future Outlook: The clinical history of cyproterone acetate serves as a critical case study in the importance of long-term pharmacovigilance, especially for drugs with profound and sustained hormonal effects. Future research should aim to identify genetic or clinical markers that could predict which patients are at the highest risk for developing severe adverse events like meningioma or hepatotoxicity. Further studies are also warranted to establish the minimum effective doses for all its indications, thereby optimizing its therapeutic index and ensuring that its potent benefits can be accessed with the lowest possible risk.

Works cited

1. Cyproterone Acetate | C24H29ClO4 | CID 9880 - PubChem, accessed September 28, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Cyproterone-Acetate
2. Cyproterone acetate | 427-51-0 - ChemicalBook, accessed September 28, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7338955.htm
3. Cyproterone acetate: Uses, Interactions, Mechanism of Action ..., accessed September 28, 2025, https://go.drugbank.com/drugs/DB04839
4. Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer, accessed September 28, 2025, https://pubmed.ncbi.nlm.nih.gov/7919640/
5. Cyproterone Acetate (Apo) | healthdirect, accessed September 28, 2025, https://www.healthdirect.gov.au/medicines/brand/amt,1277291000168108/cyproterone-acetate-apo
6. Cyproterone-containing medicinal products - referral | European Medicines Agency (EMA), accessed September 28, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/cyproterone-containing-medicinal-products
7. (PDF) Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures - ResearchGate, accessed September 28, 2025, https://www.researchgate.net/publication/377857701_Physician_Awareness_of_the_Safe_Use_of_Cyproterone_Acetate_in_Europe_A_Survey_on_the_Effectiveness_of_Additional_Risk_Minimization_Measures
8. www.ncbi.nlm.nih.gov, accessed September 28, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548024/#:~:text=(Textbook%20of%20pharmacology%20and%20therapeutics,bicalutamide%2C%20flutamide%20and%20nilutamide).
9. Cyproterone acetate (Cyprostat) - Cancer Research UK, accessed September 28, 2025, https://www.cancerresearchuk.org/about-cancer/treatment/drugs/cyproterone-acetate
10. Cyproterone acetate - Wikipedia, accessed September 28, 2025, https://en.wikipedia.org/wiki/Cyproterone_acetate
11. Cyproterone acetate–ethinyl estradiol use in a 23-year-old woman with stroke - PMC, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4049993/
12. Search Orphan Drug Designations and Approvals - FDA, accessed September 28, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=3884
13. Cyproterone Acetate | CAS 427-51-0 | SCBT - Santa Cruz Biotechnology, accessed September 28, 2025, https://www.scbt.com/p/cyproterone-acetate-427-51-0
14. Cyproterone Acetate (CAS 427-51-0) - Cayman Chemical, accessed September 28, 2025, https://www.caymanchem.com/product/16622/cyproterone-acetate
15. Cyproterone acetate = 98 427-51-0 - Sigma-Aldrich, accessed September 28, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/c3412
16. Cyproterone - Wikipedia, accessed September 28, 2025, https://en.wikipedia.org/wiki/Cyproterone
17. www.smolecule.com, accessed September 28, 2025, https://www.smolecule.com/products/s524806#:~:text=Cyproterone%20acetate%20is%20a%20synthetic,of%20approximately%20416.95%20g%2Fmol.
18. Cyproterone Acetate 427-51-0 | TCI AMERICA, accessed September 28, 2025, https://www.tcichemicals.com/US/en/p/C2942
19. New Zealand Data Sheet - Medsafe, accessed September 28, 2025, https://www.medsafe.govt.nz/profs/datasheet/p/procurtab.pdf
20. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrANDROCUR cyproterone acetate tablets Tablets, 50 mg, Oral PrANDROC, accessed September 28, 2025, https://pdf.hres.ca/dpd_pm/00080518.PDF
21. Cyproterone acetate - Treatment and side effects - Macmillan Cancer Support, accessed September 28, 2025, https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/cyproterone-acetate
22. Cyproterone acetate (Standard) | Androgen Receptor Antagonist | MedChemExpress, accessed September 28, 2025, https://www.medchemexpress.com/cyproterone-acetate-standard.html
23. Cyproterone Acetate|Androgen receptor antagonist - APExBIO, accessed September 28, 2025, https://www.apexbt.com/cyproterone-acetate.html
24. PRODUCT MONOGRAPH MYLAN-CYPROTERONE Cyproterone Acetate Tablets 50 mg House standard ANTIANDROGEN Mylan Pharmaceuticals ULC 85, accessed September 28, 2025, https://pdf.hres.ca/dpd_pm/00011374.PDF
25. Cyproterone Acetate Tablets BP 50 mg Antiandrogen - E-lactancia, accessed September 28, 2025, https://e-lactancia.org/media/papers/Cyproterone-PM-AAPharma2010.pdf
26. PRAC February 2020 : recommendations for cyproterone containing medicinal products., accessed September 28, 2025, https://www.famhp.be/en/news/prac_february_2020_recommendations_for_cyproterone_containing_medicinal_products
27. Cyprostat 50 mg tablet - Patient Information Leaflet (PIL) - (emc ..., accessed September 28, 2025, https://www.medicines.org.uk/emc/product/15997/pil
28. Androcur - Healthdirect, accessed September 28, 2025, https://www.healthdirect.gov.au/medicines/brand/amt,3109011000036105/androcur
29. Cyproterone Acetate (GenRx) - Healthdirect, accessed September 28, 2025, https://www.healthdirect.gov.au/medicines/brand/amt,3476011000036106/cyproterone-acetate-genrx
30. Off-Label Use of Androcur for Contraception: An Expert Committee Review, accessed September 28, 2025, https://canadacommons.ca/artifacts/2063866/utilisation-dandrocur-pour-la-contraception/2816957/
31. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8571811/
32. What is Cyproterone Acetate used for? - Patsnap Synapse, accessed September 28, 2025, https://synapse.patsnap.com/article/what-is-cyproterone-acetate-used-for
33. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study - PubMed, accessed September 28, 2025, https://pubmed.ncbi.nlm.nih.gov/34125226/
34. Treatment: Polycystic ovary syndrome. - NHS, accessed September 28, 2025, https://www.nhs.uk/conditions/polycystic-ovary-syndrome-pcos/treatment/
35. Antiandrogenic Therapy with Ciproterone Acetate in Female Patients Who Suffer from Both Androgenetic Alopecia and Acne Vulgaris, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4620668/
36. Cyproterone acetate Completed Phase 4 Trials for Acne Vulgaris Treatment - DrugBank, accessed September 28, 2025, https://go.drugbank.com/drugs/DB04839/clinical_trials?conditions=DBCOND0029828&phase=4&purpose=treatment&status=completed
37. Cyproterone acetate Completed Phase 3 Trials for Prostate Cancer Treatment - DrugBank, accessed September 28, 2025, https://go.drugbank.com/drugs/DB04839/clinical_trials?conditions=DBCOND0062462&phase=3&purpose=treatment&status=completed
38. Side effects of cyproterone acetate - Wikipedia, accessed September 28, 2025, https://en.wikipedia.org/wiki/Side_effects_of_cyproterone_acetate
39. Cyproterone (oral route, intramuscular route) - Side effects & dosage - Mayo Clinic, accessed September 28, 2025, https://www.mayoclinic.org/drugs-supplements/cyproterone-oral-route-intramuscular-route/description/drg-20067981
40. Androcur - NPS MedicineWise, accessed September 28, 2025, https://www.nps.org.au/medicine-finder/androcur-tablets
41. Cyproterone AN 50 mg tablets - Main Header, accessed September 28, 2025, https://www.nps.org.au/assets/medicines/e3d05cb2-f07b-41dc-bfd9-a53300ff96ca.pdf
42. Part II Summary of Product Characteristics - HPRA, accessed September 28, 2025, https://assets.hpra.ie/products/Human/17116/LicenseSPC_PA0405-032-001_28102005115403.pdf
43. Showing BioInteractions for Cyproterone acetate (DB04839) | DrugBank Online, accessed September 28, 2025, https://go.drugbank.com/drugs/DB04839/biointeractions
44. CYPROTERONE AN cyproterone acetate 100mg tablet bottle (184234), accessed September 28, 2025, https://www.tga.gov.au/resources/artg/184234
45. FDA Advisory No.2021-2571 || Public Health Warning Against the Purchase and Use of the Following Unregistered Drug Products, accessed September 28, 2025, https://www.fda.gov.ph/fda-advisory-no-2021-2571-public-health-warning-against-the-purchase-and-use-of-the-following-unregistered-drug-products/